Open access peer-reviewed chapter
By Nemanja Zdravkovic, Mirko Rosic, Mitar Lutovac and Vladimir Zdravkovic
Submitted: June 20th 2017Reviewed: November 6th 2017Published: December 20th 2017
DOI: 10.5772/intechopen.72200
Downloaded: 1324
Cytokines are small, short-lived proteins secreted by many different cell types. As signaling molecules, cytokines provide communication between cells and play a crucial role in modulating innate and adaptive immune response. The family of cytokines includes interferons, interleukins, chemokines, mesenchymal growth factors, tumor necrosis factor family and adipokines. Interferons (IFNs) are a multigene family of inducible cytokines with antiviral, antiproliferative, and immunomodulatory function. Recombinant DNA technology can be useful in the production of human IFNs. This process includes fermentation, purification, and formation of the final product. Interleukins are classified in families based on sequence homology, receptor-binding properties, biological function, and cellular sources. TNF and IL-1 are considered to be key mediators of inflammatory response, while IL-6 plays a key role in the transition from acute to chronic inflammation. The inhibition of TNF includes administration of anti-TNF antibody and TNF receptor (TNFR). The reduction of IL-1 level can be achieved by the administration of anti-IL-1 antibody or IL-1 receptor antagonist (IL-1Ra), and the reduction of IL-6 level in the treatment of chronic inflammatory diseases can be achieved by the administration of anti-IL-6 antibody and anti-IL-6 receptor antibody. Recombinant cytokines and cytokine antagonists (antibodies and receptors) can be used in treating many different diseases.
Cytokines are low molecular weight proteins or glycoproteins secreted by a number of cell types. The term cytokine is made up of two parts: cyto (cell) and kine (movement) [1]. As signaling molecules, cytokines provide communication between cells and play a crucial role in modulating of the innate and adaptive immune response (Table 1).
| Family | Members | Functions |
|---|---|---|
| IL-1 family | ||
| IL-1 subfamily | Agonist activity | |
| IL-1α (IL-1F1) | Induction of proinflammatory response Th17 cell differentiation | |
| IL-1β (IL-1F2) | Induction of proinflammatory response Th17 cell differentiation | |
| IL-33(IL-1F11) | Acts as an alarmin Induction of Th2 response Activation of ILC2 cells Th1 cell differentiation dependent on IL-12 Induction of Treg cells | |
| Receptor antagonists | ||
| IL-1Ra (IL-1F3) | Antagonism of IL-1 | |
| IL-18 subfamily | Agonist activity | |
| IL-18(IL-1F4) | Induction of IFN-γ in presence of IL-12 Enhances NK cell cytotoxicity Promoting Th1 or Th2 cell responses depending cytokine milieu Activation and cytokines release from neutrophils | |
| Antiinflammatory activity | ||
| IL-37 (IL-1F7) | Suppression the production of proinflamatory cytokines Inhibition of dendritic cells (DCs) function (foremost through stimulation of TGF-β) | |
| IL-36 subfamily | Agonist activity | |
| IL-36α(IL-1F6) | Promoting Th1 and Th17 cell responses (skin, lungs, kidneys) | |
| IL-36β (IL-1F8) | Promoting Th1 and Th17 cell responses (joints) | |
| IL-36γ(IL-1F9) | Promoting Th1 and Th17 cell responses (lungs) | |
| Receptor antagonists | ||
| IL-36Ra(IL-1F5) | Antagonism of IL-36-α, IL-36-β and IL-36γ Antiinflammatory brain action via induction of IL-4 expression in glia cells | |
| IL-38(IL-1F10) | Antagonism of IL-36-α, IL-36-β and IL-36γ Inhibits the production of IL-17 and IL-22 Inhibits the production of IL-8 induced by IL-36γ | |
| Common γ chain cytokine family | ||
| IL-2 | Proliferation and differentiation into effector and memory T cells Development of Treg cells Proliferation of B cells Proliferation and differentiation of NK cells | |
| IL-4 | Th2 cell differentiation IgE class switching Antagonise the effects of IFN-γ Alternative activation of macrophages (M2 phenotype) Upregulation of class II MHC molecules expression on B cells and monocytes Upregulation of FcεRII (CD23) and IL-4R Survival factor for B and T cells Role in tissue adhesion and inflammation | |
| IL-7 | Proliferation of early T and B cell progenitors Naive and memory T cell survival Development of γδT cells (VDJ recombination of TCRγ) Induction of CTLs and LAK cells | |
| IL-9 | CD4+ T cells and mast cells growth factor Proliferation of CD8+ T cells and mast cells Inhibition of Th1 cytokines Promotes Th17 cell differentiation IgE production Chemokine and mucus production in bronchial epithelial cells | |
| IL-15 | Induction of Th1 and Th17 responses Activation of T cell (decreased TCR activation threshold) Survival and proliferation of memory CD8+ T cells Loss of Treg cells- and TGF-β immunoregulation Suppression of IL-2 induced AICD of T cells Differentiation of γδT cells Proliferation and activation of NK cells Homeostasis of NK and NKT cells Induction of LAK cells | |
| IL-21 | Regulation of B cell proliferation, differentiation and apoptosis Antibody isotype balance (increased IgG and decreased IgE) Generation of long-lived plasma cells and T cell-dependent antigen responses and memory T cell and NK cell proliferation Increases cytotoxic activity of NK cells and CTL cells Induces the differentiation of T follicular helper (TFH) cells Expansion of Th17 cells Inhibits DC activation and maturation | |
| IL-6 family | ||
| IL-6 | Synthesis of acute phase proteins in liver Inducing secretion of chemokines: CCL2, CCL8, CXCL5, CXCL6 Induction of neutrophil apoptosis Switching from neutrophil to monocyte recruitment Transition from innate to acquired immunity Direct mediator of T cell migration T cell differentiation, activation and survival B cell differentiation and production of IgG, IgM, IgA Survival of hematopoietic stem cells and early progenitors Proliferation and differentiation of myeloid, erythroid, megakaryocyte progenitors Survival factor for neuronal cells | |
| IL-11 | Synthesis of acute phase proteins in liver Growth factor for myeloid, erythroid, megakaryocyte progenitors Bone remodeling Protects epithelial cells and connective tissue Inhibition of macrophage activity Inhibition of adipogenesis Promotion of neuronal development | |
| IL-31 | Induction of IL-1β, IL-6, IL-8, GRO-α (CXCL1), MCP-1 (CCL2) and DC-CK1 (CCL18) production in eosinophils Increased chemokines mRNA expression (GRO-α (CXCL1), TARC (CCL17), MIP-3β (CCL19), MDC (CCL22), MIP-3 (CCL23), MIP-1β (CCL4)) in keratinocytes Antiapoptotic effect on eosinophils Expression of growth factors and chemokines in epithelial cells Inhibition of proliferation and apoptosis in epithelial cells | |
| Leukemia inhibitory factor (LIF) | Self-renewal and block in differentiation embryonic stem cell Embryonic implantation (receptive state of endometrial, the interaction between endometrial and embryo, stromal decidualization, the invasion of blastocyst, blastocyst development, infiltration of uterine leukocytes, synthesis of prostaglandins) Anti-inflammatory effect Neuronal development | |
| Oncostatin M (OSM) | Maintenance of erythroid and megakaryocyte progenitor pools in BM by regulation hematopoietic cytokine production in stromal cells and direct effect on erythrocytic and megakaryocytic progenitors Tumor suppression Neuronal development | |
| IL-10 family | ||
| IL-10 | Immune suppression Inhibition of expression IL-12, costimulators , and class II MHC molecules on macrophages and DCs Inhibition of proliferation CD4+ T cells and production of IL-2, IFN-γ, IL-4, IL-5 and TNF-α Enhancing Treg cells function (suppressing autoreactive T cells) Reduces immune suppression of autoreactive B cells and enhances antibody production | |
| IL-20 subfamily | IL-19 | Enhances the production of Th2 cytokines Induces IL-6, IL-8 and IL-10 production in monocytes Alternative activation of macrophages (M2 phenotype) Induction of angiogenesis Role in skin inflammation (psoriasis) Production of antimicrobial peptides (S100A7 (also known as psoriasin), S100A8, S100A9, and β-defensins) and barrier function increase |
| IL-20 | Role in skin inflammation (psoriasis) Development of hematopoietic cells Production of antimicrobial peptides (S100A7 (also known as psoriasin), S100A8, S100A9, and β-defensins) and barrier function increase Inhibition of neutrophil phagocytosis, granule exocytosis,and migration | |
| IL-22 | Controlling the intestinal microbiota Production of antimicrobial peptides (S100A7 (also known as psoriasin), S100A8, S100A9, and β-defensins) and barrier function increase Wound healing Tissue regeneration (intestine, liver, thymus, pancreas and kidneys) Role in skin inflammation (psoriasis) | |
| IL-24 | Tumor suppression (loss of proliferative capacity) Production of antimicrobial peptides (S100A7 (also known as psoriasin), S100A8, S100A9, and β-defensins) and barrier function increase Role in skin inflammation (psoriasis) | |
| IL-26 | Production of proinflammatory cytokines (IL-1β, IL-6, TNF and CCL20) Th17 cell differentiation Direct killing of bacteria | |
| See Type III interferons | IL-28A (IFN-λ2) IL-28B (IFN-λ3) IL-29 (IFN-λ1) | |
| IL-12 family | ||
| IL-12 | Th1 cell differentiation Increases cytotoxic activity of NK cells and CD8+ T cells and production of IFN-γ Antiangiogenic effect | |
| IL-23 | Th17 cell expansion, maintaining activation and secretion of IL-17A, IL-17F, IL-22 and GM-CSF Dependent pathogenicity of Th17 cells Stimulation of macrophages to produce TNF, IL-1 | |
| IL-27 | Pro- and anti-inflammatory effects (induction of Th1 response and suppressive effect on CD4+ T cell production of IL-2, inhibition of Th2, Th17 and iTreg cells) Limits the intensity and duration of innate and adaptive immune responses | |
| IL-35 | Induction of Treg cells proliferation Inhibition of Th17 response | |
| IL-17 family | ||
| IL-17A IL-17F | Induction of proinflamatory cytokines, chemokines, and metalloproteases (controlling bacterial and fungal infection) Modulation of viral infection Recruitment of neutrophils | |
| IL-17B IL-17C IL-17D | Induction of proinflamatory cytokines, chemokines, and metalloproteases | |
| IL-25 (IL17E) | Induction of Th2 response | |
| Th2 like cytokines | ||
| IL-5 | Differentiation and function of myeloid cells Increment of chemotactic activity and adhesion capacity on eosinophils Remodeling and wound healing | |
| IL-13 | Switching to IgE Antagonises the effects of IFN-γ Upregulation of FcεRII (CD23) and class II MHC molecules expression on B cells and monocytes Alternative activation of macrophages (M2 phenotype) Activation of eosinophils and mast cells Recruitment and survival of eosinophils Defense against parasite infections (mucus production) | |
| Chemokine activities | ||
| IL-8 | Chemoattractant for neutrophils, NK cells, T cells, basophils, eosinophils Induces phagocytosis Mobilisation of hematopoietic stem cells Angiogenesis | |
| IL-16 | Chemoattractant for cells with CD4 molecule Modulation of T cell response | |
| Non-classified | ||
| IL-3 | Induces maturation of all hematopoietic lineages Activation of basophils Activation and survival of eosinophils | |
| IL-14 | Induces growth and proliferation of B cells and inhibits antibody secretion | |
| IL-32 | Induction of TNF-α, IL-6 and IL-8 Induction of apoptosis | |
| IL-34 | Differentiation and viability of monocytes and macrophages | |
| Type I interferons | ||
| IFN-α (13 subtypes) | Antiviral state Increases the expression of class I MHC molecules Activation of NK cells | |
| IFN-β | Antiviral state Increases the expression of class I MHC molecules Activation of NK cells | |
| IFN-κ IFN-ω IFN-ɛ IFN-δ (pigs) IFN-ζ IFN-τ (ruminant) IFN-v | Antiviral response | |
| Type II interferons | ||
| IFN-γ | Th1 cell differentiation Classical activation of macrophages (increased microbicidal functions) Promotes cytotoxic activity Isotype switching to opsonisation and complement-fixing IgG subclasses (established in mice) Upregulation of class I and class II MHC molecules Increases antigen processing and presentation to T cells Antiviral properties Inhibition of cell growth Proapoptotic effects | |
| Type III interferons | ||
| IL-28A (IFN-λ2) IL-28B (IFN-λ3) | Antiviral response Promotes cytotoxic activity | |
| IL-29 (IFN-λ1) | Antiviral response | |
| IFN-λ4 | Antiviral response Impairs HCV antiviral program or clearance by impeding receptor binding of the other members of the IFN-λ family | |
| TNF superfamily | TNF | Induction of inflammation (vasodilatation, edema, facilitation of the adhesion of leukocytes, production of reactive oxygen species) Induction of intravascular thrombosis Fever occurrence Induces secretion of IL-6 from leukocytes Loss of appetite, wasting of muscle and fat cells (cachexia) Induction of insulin resistance Inhibits myocardial contractility and vascular smooth muscle tone (low blood pressure) Stimulates capillary leak |
Characteristics of cytokines.
Nomenclature of cytokines was created either according to the type of cells which secrete them (in this case named interleukins and adipokines) or biological activity (in this case named interferons, chemokines, mesenchymal growth factors and tumor necrosis factor family). This nomenclature is still used [2]. There are several basic common properties of cytokines which are important in understanding their effect in the human body:
Synthesis of cytokine is mainly induced by various stimuli which act on cells. Also they can exist in preformed granules which are constitutively produced and secreted from cells.
Cytokines achieve their effects by binding with high affinity to specific membrane receptors on cells. Therefore, cells show a relatively small number of specific cytokine receptors (100–1000 per cell). In other words, very low concentrations of cytokines can trigger biological effects in cells. Cellular response to the effects of cytokines is well regulated and it is reflected in the changes of gene expression in target cells resulting in the expression of new functions.
Cytokines exert effects on different types of cells (the same cells express a variety of cytokine receptors), or one cytokine can exert many different biological effects. This cytokine action is called pleiotropy. Also, several cytokines share the same functional effects, and various cytokines can have the same or similar biological activity (various cytokines activate the same signaling pathways) which is called redundancy [3].
Cytokines affect the synthesis and the activity of other cytokines, acting antagonistically, additively or synergistically.
Cytokine activity can be autocrine (on the very cell that secretes it), paracrine (on surrounding cells) and endocrine (in distant cites from the production). Basic characteristics of cytokines suggest that their implementation achieves complex effects which are often accompanied by numerous side effects.
Interferons (IFNs) consist of multigene family of inducible cytokines with predominantly antiviral activity [4]. Interferons were detected more than 50 years ago as a soluble substance which inhibits the replication of influenza virus. They were named after their ability to interfere (hinder) the replication in host cells protecting healthy cells from viral infection [5]. The family of interferons is now described as a key component of innate immune response and the first line of defense against viral infections. Interferons are proteins that synthesize and produce host cells in response to the presence of various pathogens: viruses, bacteria and parasites. As signaling molecules they provide communication between cells for the purpose of activating and directing the immune response in order to eliminate the pathogen in the most effective way. Due to the fact that interferons belong to the cytokine family, they influence the processes of proliferation, differentiation and apoptosis, and exhibit a number of immunomodulatory functions. According to the type of receptor complex via which they transmit the signal, all interferons are classified into three classes (Type I, II and III). This means that interferons can achieve their activity over three receptor complexes. Type I (IFN-α, IFN-β) and type III interferons have been identified as antiviral types, and type II (IFN-γ) is known as the immune interferon.
Antiviral and antiproliferative activity of interferons, as well as their ability to modulate immune and inflammatory responses, make them highly applicable in medical treatment [6]. There are many preparations of interferons which are approved for clinical use. Further clinical studies are conducted presently. It is expected that the obtained results will enable a wider application of interferons for medical purposes. Although it became clear in XX century that the possibilities for therapeutic application of interferons are huge, the following issues had to be resolved in order to find their wider application in medicine:
An extremely low level of interferons is produced in the human body.
Interferons show species specificity, which implies that only human interferons can be used for human clinical treatments.
Since interferons were grown from human leukocytes present in blood transfusion stocks until the 1970s of the last century, their massive production was virtually untenable. In fact, this method provided a mixture of various types and subtypes of interferons in different quantities. However, clinical studies conducted with modest amounts of insufficiently treated interferon preparations have yielded encouraging results. A significant production of interferons was achieved by mammalian cell lines used in the late 1970s. A variety of tumor cell lines was tested first and it was revealed that Namalwa cell line (a type of human lymphoblastic cell) produced a large amount of interferons [7]. The exposure of these cells to certain viruses (typically Sendai virus) caused an increased production of IFN. Subsequent analysis showed that the final product contains thirteen subtypes of IFN-α, which is why it was necessary to introduce new production technologies. Nowadays, the recombinant DNA technology is used to obtain individual interferon (sub) types. The production of the desired interferon is achieved by insertion of specific genes using vectors for interferons (usually a virus) in mammalian cell lines (Chinese Hamster Ovary - CHO, monkey kidney, etc.), bacteria Escherichia coli (E. coli) or fungi. Although around 70% of pharmaceutical recombinant proteins currently used for medical purposes is produced in mammalian cells, interferons are produced mainly in E. coli. The purification of interferons aims to obtain a final product with 99% level purity, which is mainly achieved by using chromatographic techniques (metal-chelate affinity chromatography, exclusion chromatography (gel filtration), ion-exchange chromatography). Finally, the quality and quantity of interferons are checked by monoclonal antibodies and their effects are analyzed on biological material by different biological assays.
Interferon production process includes the fermentation process, purification and the formation of the final product. Fermentation is conducted in specially designed vessels made of stainless steel. This process involves transfer and expression of genes in E. coli and the subsequent intracytoplasmic protein production of the inserted gene. Thus, recombinant proteins constitute intracytoplasmic accumulation of inclusion bodies. Homogenization E. coli and centrifugation, followed by a chromatographic purification process, need to be done in order to prepare inclusion bodies. The crystallization method is used for the final purification of interferons. The crystallized product is then dissolved in a phosphate buffer which contains glycine and human albumin (carriers of an active substance). Finally, lyophilization and packaging of the product is done.
There are several significant advantages achieved by the modification of interferons. Recombinant interferon modification is achieved by the process of “pegylation.” This process was first described by Frank Davis and Abraham Abuchowski and his associates in 1977 [8]. In contrast to the modification process of drug formulation (using colloidal systems or osmotic pumps), the process of interferon pegylation involves covalently binding polyethylene glycol (PEG) polymer chain to the amino group of interferons, which significantly improves its pharmacokinetic and pharmacodynamic characteristics [9]. Many existing pharmacological limitations of interferons are overcome by the process pegylation. Native PEG is an inert, nontoxic polymer with two terminal hydroxyl groups. Chemically active form of PEG molecule is obtained by modifying the terminal hydroxyl group (substitution process of a hydroxyl group with reactive (functional) one). The incubation of purified interferon with methoxypolyethylene glycol (chemically active form of PEG) spontaneously forms covalent bonds [10]. There are different configurations of PEG molecules today, including linear and branched structures of various molecular weights. Formation of stable (covalent) bonds in the process of pegylation of interferon is necessary for a long-term preservation of incurred pharmacological changes. Resultant molecules of interferon are predominantly monopegylated with small impurities of di-, and non-pegylated molecules. Sodium phosphate, saccharose and polysorbate are used as carriers of the active substance for the pegylated product in lyophilized form.
After subcutaneous administration IFN-α is rapidly absorbed and the peak of serum concentration is reached 7–12 hours after which its concentration decreases rapidly. As half-life of IFN-α is 3–8 hours, its serum concentration falls below detection limit within 24 hours after administration [11]. Since the administration of IFN-α is conducted 3 times a week, the desired serum concentration is not maintained in most intervals between applications.
Different linear and branched structures of PEG molecules are used for the pegylation of IFN-α, so that the resulting preparations exhibit different pharmacokinetic and pharmacodynamic characteristics which are improved in comparison to standard IFN-α. PEG group protects IFN-α from enzymatic degradation, prolongs the absorption period at the administration site of subcutaneous injection and reduces its clearance from the body, so the period to reach maximum concentration is significantly prolonged (80 hours). Taking into consideration the above mentioned, it is clear that IFN-α concentration in blood is higher and more constant for a much longer period of time when compared to standard IFN-α. These pharmacokinetic properties enable once-a-week subcutaneous administration of pegylated IFN-α to achieve and maintain the concentration in blood that provides the desired effectiveness (desired effects are time and concentration dependent). Pegylation of IFN-α greatly improves its pharmacodynamic characteristics, and testing shows 100 times stronger antiviral activity and 20 times stronger antitumor activity. Nowadays, IFN-α is used in the treatment of hepatitis B and C, chronic myeloid leukemia, malignant melanoma, non-Hodgkin’s lymphoma, Kaposi’s sarcoma, and other diseases (Table 2).
| Generic name | Trade name | Treatment | Year of first FDA approval | Company |
|---|---|---|---|---|
| IFN-α − con-1 | Infergen | Chronic hepatitis C | 1997 | Amgen |
| IFN-α − n3, leukocyte derived | Alferon-N | Condylomata acuminata | 1989 | Hemisperx Biopharma |
| IFN-α − 2a, pegylated | Pegasys | Chronic hepatitis C Chronic hepatitis B | 2002 | Roche |
| IFN-α − 2a, recombinant | Roferon-A | Chronic hepatitis C Hairy cell leukemia Kaposi’s sarcoma Chronic myeloid leukemia | 1986 | Roche |
| IFN-α − 2b, pegylated | PEG-Intron | Chronic hepatitis C | 2001 | Schering-Plow |
| IFN-α − 2b, pegylated | Sylatron | Malignant melanoma | 2011 | Schering-Plow |
| IFN-α − 2b, recombinant | Intron-A | Hairy cell leukemia Kaposi’s sarcoma Chronic hepatitis B/C Malignant melanoma Follicular lymphoma Condylomata acuminata | 1997 | Schering-Plow |
IFN-α approved by FDA for therapeutic use.
There are several preparations made of IFN-β used for therapeutic purposes. Some of them were made by recombinant DNA technology in E. coli, but nowadays CHO cell line is mostly used in their production [12]. Recombinant human IFN-β produced in CHO cell line (rhIFN-β-1a) is glycosylated and it has the same amino acid sequence as natural IFN-β [13, 14]. Although E. coli does not generate glycosylation of IFN-β [15], this deficiency does not affect the efficiency of its therapeutic applications. IFN-β is presently used in the treatment of multiple sclerosis. However, in IFN-β glycans play an important role in the protein stabilization and thus enhance its biological activity [16] (Table 3).
| Generic name | Trade name | Treatment | Year of first FDA approval | Company |
|---|---|---|---|---|
| IFN-β − 1a | Avonex | Relapsing multiple sclerosis High risk for MS | 1996 | Biogen IDEC |
| IFN-β − 1b | Betaseron | Relapsing multiple sclerosis High risk for MS | 1993 | Berlex |
| IFN-β − 1b | Extavia | Relapsing multiple sclerosis | 2009 | Novartis |
IFN-β approved by FDA for therapeutic use.
IFN-γ preparations are made by recombinant DNA technology in bacteria E. coli. Despite the fact that recombinant human IFN-γ is not glycosylated [17], its biological activity is not affected. It is used for the treatment of chronic granulomatous disease (Table 4).
| Generic name | Trade name | Treatment | Year of first FDA approval | Company |
|---|---|---|---|---|
| IFN-γ − 1b, bioengineered | Actimmune | Chronic granulomatous disease Malignant osteopetrosis | 1990 | Intermune Pharma |
IFN-γ approved by FDA for therapeutic use.
Administration of interferons can cause many side effects [18].
Application of IFN-α causes increased temperature, chills and headache. These reactions are often manifested a few weeks after the application and paracetamol is simultaneously applied to alleviate them. Severe cases develop anorexia, insomnia, cardiovascular complications and autoimmune reactions, which requires immediate termination of its application.
Application of IFN-β causes increased temperature, chills and headache. Severe cases develop hypersensitivity reactions, depression and menstrual disorders.
Application of IFN-γ causes increased temperature, chills and headache. Severe cases develop heart failure, metabolic disorders and disorientation.
More than 40 interleukins with different properties are known today. Interleukins are classified in families based on sequence homology, receptor-binding properties, biological function and cellular sources.
There are 38 interleukins which are designated by the abbreviation IL (from Interleukin) and Arabic numbers [19]. Interleukins are produced by various types of body cells, wherein the specific interleukins (IL-1) can be secreted by up to 20 different cell types. Most cells capable of synthesizing one interleukin are capable of synthesizing several different. Today, the recombinant DNA technology is used for interleukin production, enabling quantities sufficient to meet demanding medical needs.
IL-1 is a proinflammatory cytokine which stimulates the synthesis of substances involved in the induction of inflammation. Activated mononuclear phagocytes are the main cellular source of IL-1. When secreted in small quantities, IL-1 acts as a paracrine mediator of local inflammation, while in larger amounts the endocrine effect can induce body temperature increase, synthesis of acute-phase proteins in the liver and the production of neutrophils and platelets in the bone marrow. In diseases with the elevated level of IL-1 it is important to decrease IL-1 level due to its effect in the induction of inflammation [20]. It has been shown that preparations which reduce the level of IL-1 are therapeutically useful when administered alone or, more preferably, in the combination with low doses of other therapeutic agents. In accordance with the above, the reduction of IL-1 level can be achieved by the administration of:
Anti-IL-1 antibody
The IL-1 receptor antagonist (IL-1Ra)
Canakinumab is a human anti-IL-1ß monoclonal antibody which is administered subcutaneously for the treatment of syndromes associated with periodic cryopyrin (CAPS—cryopyrin associated periodic syndromes). The main sign of CAPS is urticaria with neutrophilia, accompanied by high fever, headache and arthralgia.
Anakinra/Kineret is a recombinant, nonglycosylated form of human interleukin-1 receptor antagonist (IL-1Ra). Anakinra is different from native human IL-1Ra as it is non-glycosylated and may contain an additional N-terminal methionine residue at its amino-terminus, as the result of its production by recombinant DNA technology in prokaryotic system (E. coli). In people suffering from rheumatoid arthritis an elevated level of IL-1 is present in the synovial fluid of joints affected. IL-1 shows negative effects on the joints and bones, which include degradation of cartilage and stimulates bone resorption. Therefore, in patients suffering from rheumatoid arthritis the subcutaneous injection of 100 mg (0.67 ml) of Anakinra is administered daily. The following substances are present as carriers of active substance in the final product: sodium citrate (1.29 mg), ethylenediaminetetraacetic acid (EDTA) (0.12 mg), sodium chloride (5.48 mg) and polysorbate 80 (0.70 mg). It is also approved to be applied in the treatment of Neonatal-Onset Multisystem Inflammatory Disease (severe form Cryopyrin-Associated Periodic Syndromes).
As it was the case with most other cytokines, the use of IL-2 for medical purposes was initially impractical because of small production quantities. Some transformed cell lines, particularly cell line Jurkat (T cell leukemia), produced IL-2 in larger quantities [21]. The largest amounts of IL-2 used in initial studies were obtained from this source. The production of significant amounts of IL-2 is possible by the development of recombinant DNA technology. Today, complementary DNA (cDNA) to the IL-2 gene is expressed in many cell lines, while E. coli was used at the beginning (absence of glycosylation of the recombinant product does not alter biological activity of IL-2).
Basiliximab (anti-IL-2Rα (CD25); chimeric monoclonal antibody) is produced in a cell line Sp2/0 and is administered intravenously to patients after kidney transplantation. Basiliximab and cyclosporine are administered in the treatment of kidney transplant [22]. It is important to note that studies have shown that basiliximab slows cyclosporine elimination from the body (it is believed that cytochrome P450 plays an important role in this process).
Daclizumab (anti-IL-2Rα (CD25); humanized monoclonal antibody) was administered intravenously to patients after kidney transplantation. It was withdrawn from the market of the European Union and the United States of America in 2009.
Recombinant IL-2.
Proleukin (Aldesleukin) is indicated for the treatment of adults with metastatic renal cell carcinoma (year of first approval-1992) and metastatic melanoma (year of first approval-1998). Proleukin helps an increased production of several different components of the immune system found in the blood, including T lymphocytes and natural killer cells. Proleukin should be restricted to patients with healthy heart and lung function. Proleukin can cause capillary leak syndrome and the treatment is associated with a reduced neutrophil chemotaxis and with an increased risk of disseminated infection, including sepsis.
IL-6 has pro- and anti-inflammatory properties and plays a crucial role during the transition from innate to acquired immunity. It has the ability to stimulate neutrophil production, promote expansion and activation of T cells, the differentiation of B cells, and the regulation of the acute-phase response [23]. Proteolytic shedding of IL-6Rα from invading neutrophils subsequently drives IL-6 trans-signaling in resident tissue cells, leading to a switch from neutrophil to monocyte recruitment by suppressing mainly neutrophil-attracting (CXCL1, CXCL8 and CX3CL1) and enhancing mainly monocyte-attracting chemokines (CCL2, CCL8, CXCL5 and CXCL6), and cellular adhesion controlled by the lymph node–homing receptor CD62L, and modulates expression of adhesion molecules ICAM-1 and VCAM-1. Besides its role in attracting monocytes, IL-6 trans-signaling has been shown to skew monocyte differentiation toward macrophages by upregulating M-CSF receptor expression. The finding that IL-6 induces neutrophil apoptosis contributes to the resolution of acute neutrophil infiltration. Increased IL-6 level is often a better predictor of disease activity in the context of infection, autoimmunity or cancer than C-reactive protein [24, 25]. Consistent with the early description of IL-6 as a lymphocyte-stimulating factor, IL-6 deficiency leads to impaired innate and adaptive immunity to viral, parasitic and bacterial infection. Indeed, children with inhibitory autoantibodies to IL-6 develop recurrent staphylococcal cellulitis and subcutaneous abscesses. While IL-6 has a protective role in many infections, the same activity can be key to the maintenance of chronic inflammation that includes rheumatoid arthritis and multicentric Castleman’s disease. The reduction of IL-6 level (Table 5) as the treatment of chronic inflammatory diseases can be achieved by the administration of:
Anti-IL-6 antibody
Anti-IL-6 receptor antibody
| International nonproprietary name (INN) | Target | Type | Year of first EMA approval | Year of first FDA approval | Cell line | Therapeutic indication |
|---|---|---|---|---|---|---|
| Tocilizumab | IL-6R | Humanized IgG1 | 2009 | 2010 | CHO | Rheumatoid arthritis Juvenile idiopathic arthritis |
| Siltuximab | IL-6 | Chimeric IgG1 | 2014 | 2014 | CHO | Multicentric Castleman’s disease |
| Sarilumab | IL-6R | Human IgG1 | 2017 | 2017 | CHO | Rheumatoid arthritis |
Monoclonal antibodies target at IL-6/IL-6R approved by FDA and EMA for therapeutic use.
Siltuximab is a chimeric immunoglobulin (IgG)1 monoclonal antibody that binds IL-6. IL-6 antagonist is indicated for the treatment of patients with multicentric Castleman’s disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative.
Sarilumab is a human immunoglobulin (IgG)1 monoclonal antibody which binds specifically to both soluble and membrane-bound IL-6 receptors (sIL-6Rα and mIL-6Rα) and inhibits IL-6-mediated signaling. It is administered subcutaneously in a dose of 200 mg once every 2 weeks for the treatment of rheumatoid arthritis. By binding to IL-6Rα, sarilumab prevents the formation of high-affinity complex of IL-6 with IL-6Rα and thus blocks IL-6 signaling. As sarilumab blocks both mIL-6Rα and sIL-6Rα, it has the potential to inhibit both intra-articular and systemic IL-6 signaling. Patients treated with Sarilumab are at increased risk for developing serious infections.
Tumor necrosis factor (TNF) was originally described as a circulating protein which causes tumor necrosis (discovered in 1975 as endotoxin-induced glycoprotein which causes necrosis of sarcoma in mice). Human TNF was first produced in 1985 by recombinant DNA technology in E. coli [26]. Activated mononuclear phagocytes are the most important cellular source of TNF. TNF exerts a variety of effects on vascular endothelial cells and leukocytes. In response to TNF endothelial cells enhance the expression of different combinations of leukocyte adhesion molecules (including E-selectin, ICAM-1 and VCAM-1), which in combination with the secretion of chemokines (IL-8, including, MCP-1 and IP-10) from peripheral blood leukocytes and endothelial cells induces chemotaxis of different populations of leukocytes to the site of inflammation apart from the recognition of the antigen. In addition, TNF stimulates microbicidal activity of neutrophils and monocytes in order to eliminate the cause easier. Secreted in small amounts, TNF acts locally (autocrine and paracrine), primarily on vascular endothelial cells and leukocytes. The effect of TNF on the endothelium and leukocytes is most likely crucial for a successful local inflammatory response to microorganisms. TNF is produced in large quantities in severe infections. It enters the bloodstream and affects distant cites (endocrine), causing pathological and clinical effects on the body. Systemic effects caused due to excessive TNF production or exogenous administration in high doses can induce increased body temperature, synthesis of acute-phase proteins in the liver, production of neutrophils and platelets in the bone marrow. TNF is presently considered a key mediator of inflammatory response which has a wide range of effects in inflammation, infection and response to tumors. In this respect, several approaches can be useful, and this includes the administration of:
Anti-TNF antibody
TNF receptor (TNFR)
TNF
Infliximab is an anti-TNF-α antibody which binds TNF-α and blocks the inflammation induced by cytokine. Today it is successfully used in the treatment of rheumatoid arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, etc.
Adalimumab and Golimumab are human anti-TNF-α antibodies which bind to TNF-α by blocking its activity. As TNF is a primary mediator of inflammation, these antibodies are very powerful anti-inflammatory agents.
Adalimumab has been successfully used in the treatment of rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, Crohn’s disease, ulcerative colitis, etc. It is administered in the treatment of rheumatoid arthritis and ankylosing spondylitis as a subcutaneous injection in a dose of 40 mg twice a month (in severe conditions once a week). In the treatment of Crohn’s disease starting dose is 80 mg, then 40 mg every other week (in severe conditions starting dose is 160 mg).
Golimumab has been successfully used in the treatment of rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis.
Certolizumab pegol is a humanized Fab fragment of a pegylated anti-TNF antibody produced by recombinant DNA technology in E. coli. It is used in the therapy of Crohn’s disease and rheumatoid arthritis. Pegylation of Fab fragments significantly improves distribution in tissues and prolongs the half-elimination to 14 days. The lack of Fc fragment in cells prevents the antibody binding to the protective FcRn receptor (Neonatal Fc receptor).
Etanercept/Enbrel is a recombinant human hybrid protein in which extracellular domain of TNFR2 fuses with Fc fragment of IgG (Soluble p75 TNF receptor-Fc fusion). It is produced by recombinant DNA technology in a CHO cell line. After the purification and addition of the carrier (mannitol, saccharose, and trometamol), the product is lyophilized. It is used for the treatment of rheumatoid arthritis (RA) by subcutaneous injection of 25 mg dose twice a week or 50 mg once a week. It is also applied in the treatment of juvenile idiopathic arthritis, ankylozing spondylitis, psoriatic arthritis, plaque psoriasis and plaque psoriasis in children ages 4–17. Etanercept functions as a competitive inhibitor of TNF, because it prevents its binding to receptors present on cell surface. Side effects of etanercept include the development of infections and tumors, allergic reaction (hives, swelling of the face, etc.), headache and heart failure.
Tasonermin is a human TNF-α-1a produced by recombinant DNA technology in E. coli. The purified product is packed in tube vials (1 mg of active substance per bottle) as a lyophilizate. The carriers of active substance in the final product are sodium chloride, phosphate buffer and serum albumin. It is used in the treatment of soft tissue sarcoma on the limbs in order to prevent or postpone the amputation. Tasonermin is dissolved in physiological saline to a concentration of 0.2 mg/ml after which the tissue perfusion of the affected limb is done with 3–4 mg of the substance for a period of 90 minutes. Side effects of tasonermin could be local (edem, nerve damage) and systemic (arrhythmia, nausea, liver damage) if it enters the systemic circulation.
This study is partly supported by grant ON174028 from Ministry of Education, Science and Technological Development of Republic Serbia. The authors thank Marija Zdravkovic and Jelena Zdravkovic for language revision of the chapter.
© 2017 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution 3.0 License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1324total chapter downloads
1Crossref citations
Login to your personal dashboard for more detailed statistics on your publications.
Access personal reportingEdited by Nima Rezaei
By Gwendolin Simper, Alexander A. Celik, Heike Kunze-Schumacher, Rainer Blasczyk and Christina Bade-Döding
We are IntechOpen, the world's leading publisher of Open Access books. Built by scientists, for scientists. Our readership spans scientists, professors, researchers, librarians, and students, as well as business professionals. We share our knowledge and peer-reveiwed research papers with libraries, scientific and engineering societies, and also work with corporate R&D departments and government entities.
More About Us